The Federal Reserve kept rates at 3.50% to 3.75%, citing elevated inflation and Middle East uncertainty. Internal divisions sharpened the outlook.
Federal Reserve Holds Rates Steady, Signals Internal Division Over Easing Bias Read More »
American Express hiked its quarterly dividend 16% to $0.95 per share after 2025 earnings rose 15%. Income investors are watching AXP closely.
American Express raises dividend 16% to $0.95 as earnings climb 15% Read More »
Blackstone Digital Infrastructure Trust (BXDC) advances $1.8 billion REIT IPO focused on AI-driven data centers, with Blackstone anchoring $200 million. Key details for income investors.
Blackstone-Backed BXDC REIT Targets $1.8 Billion IPO with $200 Million Anchor Commitment Read More »
Michael Lickiss, formerly with Arkadios Capital, faces multiple pending customer complaints alleging fictitious notes and promissory note misconduct, including an $11M claim.
Investment advisor Matthew Wilkes (CRD# 5409004) faces two major investor claims totaling $6.8M alleging unsuitable life insurance and premium financing recommendations.
Matthew Wilkes (CRD# 5409004) Faces Multiple Investor Claims Totaling $6.8M Read More »
FINRA fined broker William Charles Burks II $10,000 and suspended him for unsuitable concentrations in non-traded REITs and BDCs. Investors may have recovery options.
Taiwan, tariffs, and the Strait of Hormuz are back on the table — and investors should be paying attention to more than just the headlines. President Trump and Chinese President Xi Jinping are meeting in
Trump vs. Xi: What This Week’s Summit Means for Your Portfolio Read More »
Alexandria Real Estate Equities is facing renewed scrutiny. The life science REIT built its empire around biotech campuses and research labs, and investors are now worried about softer demand for laboratory space and delayed lease
Interactive Brokers posted first-quarter 2026 earnings that missed some analyst expectations, sending the stock lower in after-hours trading. For a brokerage that built its reputation on rock-bottom commissions and transparent pricing, any sign of margin
Johnson & Johnson raised its full-year 2026 guidance after posting stronger-than-expected results in its medical device segment. The healthcare conglomerate now expects faster earnings growth than it projected three months ago, sending a signal that
Johnson & Johnson raises 2026 guidance: what dividend investors should know Read More »
Get free professional market insights and stock/ETF reports that contain actionable opportunities written by a former financial advisor and Capitalist who has been investing in the markets for 20+ years.
Get Free Stock Picks, Macro Market Events & Options Strategies.
